Caplin Point Laboratories · NSE: CAPLIPOINT · BSE: 524742
Q1 FY22 results · Apr–Jun 2021
Caplin Point Laboratories reported revenue from operations of ₹300.44 crore and net profit of ₹71.53 crore for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 300.44 | — | — | 278.71 | +7.8% |
| Other income | 9.21 | — | — | 9.46 | −2.6% |
| Total income | 309.65 | — | — | 288.17 | +7.5% |
| Profit before tax | 89.52 | — | — | 84.97 | +5.4% |
| Net profit for the period | 71.53 | — | — | 67.92 | +5.3% |
| Attributable to shareholders of the company | 70.85 | — | — | 66.37 | +6.8% |
| EPS, basic (₹) | 9.37 | — | — | 8.78 | +6.7% |
| Net margin (%) | 23.8 | — | 24.4 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 127.50 | 1.20 | 106x | 122.88 | +3.8% |
| Other income | 19.33 | 0.04 | 477x | 7.36 | +162.6% |
| Total income | 146.83 | 1.24 | 119x | 130.24 | +12.7% |
| Profit before tax | 69.41 | 0.56 | 124x | 44.64 | +55.5% |
| Net profit for the period | 54.55 | 0.42 | 130x | 31.49 | +73.2% |
| EPS, basic (₹) | 7.21 | 5.55 | not comparable | 4.16 | +73.3% |
| Net margin (%) | 42.8 | 35.1 | 25.6 |
Consolidated
- Filed with BSE
- 05 Aug 2021, 17:38 IST
- Board meeting
- 05 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 Aug 2021, 17:38 IST
- Board meeting
- 05 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE